sulesomab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
mouse origin 5213 167747-19-5

Description:

MoleculeDescription

Synonyms:

  • sulesomab
  • IMMU-MN3
  • LeukoScan
Sulesomab recognizes an antigenic structure shared by a surface glycoprotein (NCA-90) of granulocytes and the tumour marker, carcinoembryonic antigen (CEA). Sulesomab is indicated for diagnostic imaging for determining the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 14, 1997 EMA Immunomedics GmbH

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Radioisotope scan of bone indication 41747008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
709B6VM65P UNII
C0529257 UMLSCUI
CHEMBL2108809 ChEMBL_ID
DB13976 DRUGBANK_ID
CHEMBL2109524 ChEMBL_ID
D05944 KEGG_DRUG
7519 INN_ID
C101172 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None